Compare KOPN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | RCKT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 340.9M |
| IPO Year | 1992 | N/A |
| Metric | KOPN | RCKT |
|---|---|---|
| Price | $2.31 | $3.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $4.25 | ★ $29.12 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,602,295.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.02 | N/A |
| 52 Week Low | $0.71 | $2.19 |
| 52 Week High | $4.16 | $13.35 |
| Indicator | KOPN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 48.16 |
| Support Level | $2.40 | $3.30 |
| Resistance Level | $2.44 | $3.65 |
| Average True Range (ATR) | 0.19 | 0.19 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 11.48 | 35.09 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.